Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Cannabidiol, pharmaceutically produced with < 5 ppm THC
Cardiol Therapeutics
COVID-19
1 trial -
CardiolRx
Cardiol Therapeutics
Recurrent Pericarditis
2 trials -
CardiolRx™ Placebo is a non-aqueous solution of medium chain triglycerides with 1.0% vitamin E as anti-oxidant. CardiolRx™ Placebo is a pale yellow clear liquid. The CardiolRx™ Placebo product is essentially the same as the CardiolRx™ drug product with the exception that the placebo does not include the active drug substance, cannabidiol., CardiolRx
Cardiol Therapeutics
Recurrent Pericarditis
1 trial -
Sildenafil placebo, Remidia, 20 mg, tabletki powlekane
Cardiol Therapeutics
Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.
1 trial -
Zaroxolyn 5 mg compresse, Zaroxolyn 10 mg compresse, DIAMOX 250 mg compresse
Cardiol Therapeutics
congestive heart failure
1 trial -
Atorvastatina Teva Italia 80 mg compresse rivestite con film, Film-coated tablets, white, shaped elliptical, and coated with smooth film. The dimensions of each tablet are approximately 18.8 mm x 10.3 mm (identical to those containing atorvastatin).
Cardiol Therapeutics
Arrhythmogenic Cardiomyopathy (ACM)
1 trial -
CardiolRx
Cardiol Therapeutics
Acute Myocarditis
1 trial -
CardiolRx
Cardiol Therapeutics
Acute Myocarditis
1 trial -
Impact of CardiolRxTM on Recurrent Pericarditis: An open label Pilot Study
Cardiol Therapeutics
Recurrent Pericarditis
1 trial -
In situ injection of anti-angiogenics in patients with brain arteriovenous malformations not eligible for exclusion treatment: phase I trial (BLITZ)
Pari Pharma GmbH
Cardiology and vascular disease
1 trial -
ACETYLSALICYLIC ACID , PRASUGREL , METOPROLOL , PROPRANOLOL , ATENOLOL , CARVEDILOL , CLOPIDOGREL , BISOPROLOL , TICAGRELOR
Cardiol Therapeutics
Spontaneous Coronary Artery Dissection.
1 trial -
ACETYLSALICYLIC ACID, PRASUGREL
Cardiol Therapeutics
St-Elevated Myocardial Infartion
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources